Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Laurence Watts - Investor Relations
Mark Foley - Chief Executive Officer & President
Tobin Schilke - Chief Financial Officer

Conference Call Participants

Seamus Fernandez - Guggenheim
Chris Shibutani - Goldman Sachs
Stacy Ku - TD Cowen
David Amsellem - Piper Sandler
Annabel Samimy - Stifel
Lachlan Hanbury - William Blair
Uy Ear - Mizuho
Serge Belanger - Needham & Company
Navann Ty - BNP Paribas

Operator

Welcome to the Revance Therapeutics Second Quarter 2024 Financial Results And Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this call is being recorded today Thursday, August 8, 2024.

I will now hand the call over to your host, Laurence Watts with Revance Therapeutics. Please proceed.

Laurence Watts

Thank you, operator. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley; and Chief Financial Officer, Tobin Schilke.

During this call, management will make forward-looking statements including statements related to expectations related to product adoption and reorders, consumer needs, preferences and behavior, the benefits and value to us practices and consumers of our products, including the efficacy duration skin quality and safety of our products, future therapeutics expansion, 2024 guidance, positive adjusted EBITDA, future capital expenditures and anticipated revenue, our strategic priorities, our anticipated success, our ability to grow and take share and market opportunity and expectations and our strategy planned operations and commercialization plans and timing of those plans.

Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in our annual report on Form 10-K and a quarterly report on Form 10-Q. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. Reconciliation to GAAP to non-GAAP measures are included in our earnings release.

With that, I will turn the call over to Mark Foley, President and Chief Executive Officer of Revance. Mark?

Mark Foley

Thank you, Laurence. Good afternoon everyone and thank you for joining our second-quarter 2024 financial results conference call. The second quarter of 2024 was another period of continued progress for Revance, led by our aesthetics division and the implementation of our strategy to bring DAXXIFY to a broad audience based on strong product attributes and competitive pricing. DAXXIFY continued to show strong growth in the second quarter with a aesthetic units sold up 65% year over year and net product revenue $28.7 million, which was up 27% year over year.